查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲分子腫瘤診斷市場：按癌症類型、最終用戶和國家進行分析和預測（2024-2033）
市場調查報告書
商品編碼
1752091

歐洲分子腫瘤診斷市場：按癌症類型、最終用戶和國家進行分析和預測（2024-2033）

Europe Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 89 Pages | 商品交期: 1-5個工作天內

價格

歐洲分子腫瘤診斷市場規模預計將從 2024 年的 6.06 億美元成長到 2033 年的 15.234 億美元，複合年成長率為 10.78%。

次世代定序(NGS)、數位PCR和液態切片是推動歐洲分子腫瘤診斷市場擴張的部分技術進步，部分原因是該地區癌症成長要素的上升。這些進步有助於改善患者預後、提供更精準的治療方案並實現更早的檢測。

主要市場統計數據
預測期 2024-2033
2024年評估 6.06億美元
2033年預測 15.234億美元
複合年成長率 10.78%

然而，分子腫瘤診斷市場滲透面臨許多區域性障礙。由於醫療預算有限，分子診斷測試的高成本仍然是一項重大挑戰，尤其是在中歐和東歐國家。此外，缺乏能夠操作先進診斷設備和解讀複雜基因組數據的專業人員也阻礙了其在臨床環境中的廣泛應用。

儘管面臨諸多挑戰，歐洲市場仍在穩定成長。生物技術、製藥、診斷設備製造商和學術研究機構之間的合作，正透過加強分子診斷工具與癌症治療的整合來加速創新。為了充分發揮分子診斷在歐洲醫療保健體系中的潛力，必須努力降低檢測成本，規範支付系統，並提高醫生的基因組學素養。

市場區隔:

細分一：按癌症類型

  • 固體癌
  • 骨髓惡性腫瘤

細分 2：按最終用戶

  • 醫院和診斷中心
  • 參考實驗室
  • 製藥和生物技術公司
  • 學術和研究機構

細分3：按地區

  • 歐洲：英國、德國、法國、義大利、西班牙等。

本報告研究了歐洲分子腫瘤診斷市場，並總結了主要趨勢、市場影響因素分析、法律制度、技術和專利分析、市場規模趨勢和預測、各個細分市場、地區/主要國家、競爭格局的詳細分析以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章歐洲分子腫瘤診斷市場：產業展望

  • 全球癌症發生率和盛行率（按癌症類型分類）
    • 歐洲
  • 趨勢：現況與未來影響評估
    • 加強企業間合作
    • 增加分子腫瘤診斷生態系統中的創新產品發布和監管核准
  • 監管狀況
    • 歐洲法律要求和框架
  • COVID-19 對分子腫瘤診斷市場的影響
  • 基於液態生物檢體的分子癌症診斷
  • 實驗室測試（LDT）和體外診斷（IVD）
  • 伴隨診斷在分子腫瘤診斷市場中的作用
  • 市場動態
    • 市場促進因素
    • 市場挑戰
    • 市場機會

第2章 分子腫瘤診斷市場（按地區）

  • 區域摘要
  • 促進因素和約束因素
  • 歐洲
    • 區域概況
    • 市場成長動力
    • 市場問題
    • 按癌症類型
    • 按最終用戶
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他

第3章分子腫瘤診斷市場：競爭基準化分析與公司概況

  • 關鍵策略發展
    • 夥伴關係、合作和業務擴展
    • 新服務
    • M&A
    • 監管和法律活動
  • 企業市場占有率分析
  • 公司簡介
    • Biocartis Group NV
    • bioMerieux
    • F. Hoffmann-La Roche Ltd.
    • QIAGEN NV

第4章調查方法

Product Code: BHP3005SS

This report can be delivered in 2 working days.

Introduction to Europe Molecular Oncology Diagnostics Market

The Europe molecular oncology diagnostics market was valued at $606.0 million in 2024, and the market is expected to grow with a CAGR of 10.78% and reach $1,523.4 million by 2033. Next-generation sequencing (NGS), digital PCR, and liquid biopsy are just a few of the technological advancements driving the European molecular oncology diagnostics market's expansion. The region's rising cancer incidence is another factor. Better patient outcomes, more accurate treatment choices, and earlier detection are made possible by these advancements.

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$606.0 Million
2033 Forecast$1,523.4 Million
CAGR10.78%

However, there are a number of regional obstacles to market penetration. The high expense of molecular diagnostic testing remains a hurdle, especially in nations with relatively limited healthcare budgets in Central and Eastern Europe. Furthermore, wider clinical usage is constrained by a lack of qualified personnel who can operate sophisticated diagnostic tools and decipher complicated genomic data.

The European market continues to grow in spite of these challenges. The integration of molecular tools into routine oncology care is being supported and innovation is being accelerated by cooperative efforts involving biotech companies, pharmaceutical companies, diagnostic producers, and academic research centres. Unlocking the full potential of molecular diagnostics in cancer management across various European healthcare systems would require efforts to standardise payment regulations, lower test prices, and increase clinician genomic literacy.

Market Introduction

The market for molecular oncology diagnostics in Europe is changing dramatically as more healthcare systems embrace precision medicine methods for treating cancer. Molecular diagnostics is becoming more and more important in detecting genetic changes connected to different types of cancer, driven by the demand for earlier detection, more precise diagnosis, and customised therapy planning. Advanced testing systems that support targeted therapies and enhance treatment outcomes are becoming more and more in demand in the region.

Adoption is accelerating in Western Europe, especially in nations like Germany, the UK, and France, because to established healthcare systems, benevolent legal environments, and rising genomic research expenditures. Central and Eastern Europe is progressively catching up, though, as initiatives are being made to standardise cancer treatment internationally and increase access to molecular diagnostics.

The market is also benefiting from the continuous integration of digital health, as oncology centres and labs use genetic data platforms to make decisions in real time. Demand in the market is also being driven by growing applications in risk stratification, treatment monitoring, and early diagnosis as well as rising awareness among physicians and patients. Europe is positioned to become a major centre for molecular oncology diagnostics, influencing the direction of customised cancer treatment in a variety of clinical settings as long as public and private health authorities keep funding innovation and capacity-building.

Market Segmentation:

Segmentation 1: by Cancer Type

  • Solid Tumors
  • Hematologic Malignancies

Segmentation 2: by End User

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Segmentation 3: by Region

  • Europe - U.K., Germany, France, Italy, Spain, and Rest-of-Europe

Europe Molecular Oncology Diagnostics Market Trends, Drivers & Challenges:

Market Trends

  • Expansion of Next-Generation Sequencing (NGS) Panels: Increasing use of multiplexed NGS assays for simultaneous detection of multiple oncogenic mutations, enabling broader genomic profiling.
  • Growth of Liquid Biopsy Adoption: Rising preference for minimally invasive circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) assays to monitor treatment response and detect early relapse.
  • Integration with Immuno-Oncology: Molecular diagnostics platforms increasingly incorporate biomarkers (e.g., PD-L1, TMB) to guide immune checkpoint inhibitor therapies.
  • Emergence of Companion Diagnostics: Co-development of targeted therapies and associated diagnostic tests is accelerating regulatory approvals and market uptake.

Market Drivers

  • Rising Cancer Incidence & Aging Population: Europe's growing elderly demographic and higher cancer prevalence boost demand for precise diagnostic tools.
  • Shift Toward Precision Medicine: Clinicians and payers favor personalized treatment plans, driving investment in molecular assays that predict therapy efficacy.
  • Favorable Reimbursement Policies: Several European healthcare systems and HTA agencies are approving broader coverage for advanced genomic tests, reducing out-of-pocket costs.
  • Technological Advancements & Cost Reductions: Continuous improvements in assay sensitivity, turnaround time, and economies of scale are making molecular tests more accessible.

Market Challenges

  • High Test Development & Implementation Costs: Building validated panels and obtaining regulatory clearances remain expensive, limiting adoption in smaller hospitals.
  • Fragmented Reimbursement Landscape: Inconsistent coverage policies across EU member states and varied HTA requirements create uncertainty for providers and manufacturers.
  • Standardization & Quality Control Issues: Lack of uniform guidelines for assay validation, interpretation, and reporting can hamper cross-laboratory comparability.
  • Data Privacy & Regulatory Complexity: Strict GDPR requirements and evolving IVDR regulations increase administrative burden and slow down clinical deployment.

Some of the prominent key players in this market are:

  • Biocartis Group NV
  • bioMerieux
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Europe Molecular Oncology Diagnostics Market: Industry Outlook

  • 1.1 Global Incidence and Prevalence of Cancer (by Cancer Type)
    • 1.1.1 Europe
  • 1.2 Trends: Current and Future Impact Assessment
    • 1.2.1 Increasing Partnerships among Players
    • 1.2.2 Increasing Launch of Innovative Products and Regulatory Approvals in Molecular Oncology Diagnostics Ecosystem
  • 1.3 Regulatory Landscape
    • 1.3.1 Legal Requirements and Framework in Europe
  • 1.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market
  • 1.5 Liquid Biopsy-Based Cancer Molecular Diagnostics
  • 1.6 Laboratory-Developed Test (LDT) vs. In-Vitro Diagnostics (IVD)
  • 1.7 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market
  • 1.8 Market Dynamics
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Incidence of Cancer Cases
      • 1.8.1.2 Rising Technological Advancements in Molecular Diagnostics
      • 1.8.1.3 Growth in Biomarker Identification and Transformations in Molecular Techniques
      • 1.8.1.4 Growing Demand for Personalized Medicine
    • 1.8.2 Market Challenges
      • 1.8.2.1 Lack of Qualified Professionals
      • 1.8.2.2 High Cost of Molecular Diagnostic Kits and Assays Hindering the Adoption Rate
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Focus on Reimbursement and Medical Coverage for Molecular Oncology Diagnostics
      • 1.8.3.2 Focus on Next-Generation Ultrasensitive Molecular Diagnostics
      • 1.8.3.3 Increasing Growth Opportunities for Molecular Diagnostics Companies in Emerging Economies

2 Molecular Oncology Diagnostics Market: by Region

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Europe
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 By Cancer Type
    • 2.3.5 By End User
    • 2.3.6 Germany
      • 2.3.6.1 By Cancer Type
      • 2.3.6.2 By End User
    • 2.3.7 France
      • 2.3.7.1 By Cancer Type
      • 2.3.7.2 By End User
    • 2.3.8 U.K.
      • 2.3.8.1 By Cancer Type
      • 2.3.8.2 By End User
    • 2.3.9 Italy
      • 2.3.9.1 By Cancer Type
      • 2.3.9.2 By End User
    • 2.3.10 Spain
      • 2.3.10.1 By Cancer Type
      • 2.3.10.2 By End User
    • 2.3.11 Rest-of-Europe
      • 2.3.11.1 By Cancer Type
      • 2.3.11.2 By End User

3 Molecular Oncology Diagnostics Market - Competitive Benchmarking & Company Profiles

  • 3.1 Key Strategic Development
    • 3.1.1 Partnerships, Alliances, and Business Expansions
    • 3.1.2 New Offerings
    • 3.1.3 Mergers and Acquisitions
    • 3.1.4 Regulatory and Legal Activities
  • 3.2 Company Share Analysis
  • 3.3 Company Profiles
    • 3.3.1 Biocartis Group NV
      • 3.3.1.1 Overview
      • 3.3.1.2 Top Products
      • 3.3.1.3 Top Competitors
      • 3.3.1.4 Target Customers/End User
      • 3.3.1.5 Key Personnel
      • 3.3.1.6 Analyst View
    • 3.3.2 bioMerieux
      • 3.3.2.1 Overview
      • 3.3.2.2 Top Products
      • 3.3.2.3 Top Competitors
      • 3.3.2.4 Target Customers/End User
      • 3.3.2.5 Key Personnel
      • 3.3.2.6 Analyst View
    • 3.3.3 F. Hoffmann-La Roche Ltd.
      • 3.3.3.1 Overview
      • 3.3.3.2 Top Products
      • 3.3.3.3 Top Competitors
      • 3.3.3.4 Target Customers/End User
      • 3.3.3.5 Key Personnel
      • 3.3.3.6 Analyst View
    • 3.3.4 QIAGEN N.V.
      • 3.3.4.1 Overview
      • 3.3.4.2 Top Products
      • 3.3.4.3 Top Competitors
      • 3.3.4.4 Target Customers/End User
      • 3.3.4.5 Key Personnel
      • 3.3.4.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1 Europe Molecular Oncology Diagnostics Market, $Million, 2024, 2028, and 2033
  • Figure 2 Molecular Oncology Diagnostics Market (by Region), $Million, 2023, 2027, and 2033
  • Figure 3 Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023, 2027, and 2033
  • Figure 4 Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023, 2027, and 2033
  • Figure 5 Role of Diagnostics in Healthcare
  • Figure 6 Cancer Prevalence and Incidence (by Cancer Type), in Million, Europe, 2022
  • Figure 7 Europe In-Vitro Diagnostic Devices Regulation Regulatory Process
  • Figure 8 Technological Advances in Liquid Biopsy Analysis
  • Figure 9 List of Some Liquid Biopsy-Based Available Tests Approved by FDA/CE-IVD
  • Figure 10 Prominent FDA-Approved Companion Diagnostics
  • Figure 11 Impact Analysis of Market Navigating Factors, 2022-2033
  • Figure 12 Global Distribution of Cases and Deaths (by Cancer Type), 2022
  • Figure 13 Global Incidence for Cancer Types, 2018-2022
  • Figure 14 Germany Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 15 France Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 16 U.K. Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 17 Italy Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 18 Spain Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 19 Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2023-2033
  • Figure 20 Partnerships, Alliances, and Business Expansions, January 2021-July 2024
  • Figure 21 New Offerings, January 2021-July 2024
  • Figure 22 Mergers and Acquisitions, January 2021-July 2024
  • Figure 23 Regulatory and Legal Activities, January 2021-July 2024
  • Figure 24 Data Triangulation
  • Figure 25 Top-Down and Bottom-Up Approach
  • Figure 26 Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Key Trends, Impact Analysis
  • Table 3: Molecular Oncology Diagnostics Market, Partnerships and Collaborations
  • Table 4: Molecular Oncology Diagnostics Market, Product Launches and Regulatory Approvals
  • Table 5: Molecular Oncology Diagnostics Market, New Offerings
  • Table 6: Biomarkers for Different Cancer Types
  • Table 7: Significance of Different Biomarkers in Clinical Outcomes of Various Cancer
  • Table 8: Cost of Liquid Biopsy-Based NGS Kits
  • Table 9: Europe Molecular Oncology Diagnostics Market, Reimbursement and Medical Coverage
  • Table 10: Molecular Oncology Diagnostics Market (by Region), $Million, 2023-2033
  • Table 11: Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 12: Europe Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 13: Europe Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 14: Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 15: Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 16: Germany Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 17: Germany Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 18: Germany Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 19: France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 20: France Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 21: France Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 22: France Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 23: U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 24: U.K. Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 25: U.K. Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 26: U.K. Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 27: Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 28: Italy Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 29: Italy Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 30: Italy Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 31: Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 32: Spain Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 33: Spain Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 34: Spain Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 35: Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2023-2033
  • Table 36: Rest-of-Europe Molecular Oncology Diagnostics Market, Cancer Type (by Solid Tumors), $Million, 2023-2033
  • Table 37: Rest-of-Europe Molecular Oncology Diagnostics Market, Cancer Type (by Hematological Malignancies), $Million, 2023-2033
  • Table 38: Rest-of-Europe Molecular Oncology Diagnostics Market (by End User), $Million, 2023-2033
  • Table 39: Europe Molecular Oncology Diagnostics Market, Company Share Analysis, 2023